Examining HSD3B1 as a possible biomarker to detect prostate cancer patients who are likely to progress on ADT

The Chemohormonal Therapy vs Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) was a randomized phase III trial that evaluated the outcomes of men with metastatic prostate cancer who received castration with or without docetaxel. Patients from this trial were gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Handy, Whitney F., Schmidt, Keith T., Price, Douglas K., Figg, William D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Journal Club
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515525/
https://www.ncbi.nlm.nih.gov/pubmed/32791030
http://dx.doi.org/10.1080/15384047.2020.1796195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515525/
https://www.ncbi.nlm.nih.gov/pubmed/32791030
http://dx.doi.org/10.1080/15384047.2020.1796195

Ejemplares similares